RE:RE:RE:RE:CeoI think a takeout because Taves is the new chair is exactly why it's likely. He's a super capital markets poobah with (undoubtedly) significant M&A chops and therefore can act as proper governance to oversee whoever they stick in as figure head CEO.
I'm hoping you're right of course and this just means that a well-respected experienced pharma person is on the front burner, but with the sector being depressed as it is, our SP being low enough to be underground and the various good things LABS does have going for it.....at even a multiple of this price it's a pretty decent bargain.....GMP cert'd facilities in OZ and Barrie now aren't that easy to come by and the global deals (while not winning any lotteries of yet) do have some value I would think....
We'll see.....but I do stand behind my very earlier comments about this year being the year of reckoning....Stada has to come through and rev's need to appreciably increase, or we may end up being a Hexo or OGI afterthought for 0.45c per share.....